Neurólogo. Subdirector del Cemcat

  • Miembro del Comité de Dirección de MAGNIMS (Magnetic Resonance Imaging in MS)
  • Miembro del Comité ejecutivo de RIMS (European network for the best practice and research in MS rehabilitation)
  • Miembro de la Junta editorial de Multiple Sclerosis Journal
  • Director de Revista de Neurología

Formación y especialidades

El Dr. Jaume Sastre-Garriga estudió Medicina en la Universitat de Barcelona, obtuvo el doctorado en la Universitat Autònoma de Barcelona y se especializó como neurólogo en el Departamento de Neurología del Hospital Universitario Vall d’Hebron.


Trayectoria profesional

De junio de 2002 a diciembre del 2004 obtuvo una beca del Ministerio de Sanidad español y ocupó una plaza como investigador clínico en las unidades de Resonancia Magnética y Neurorehabilitación del Institut of Neurology de Londres, bajo la tutoría del profesor Alan Thompson. Los años 2004 y 2005 fue galardonado por la Sociedad Española de Neurología (SEN) con el premio al mejor artículo científico español publicado en una revista de Neurología internacional. De enero de 2005 a febrero de 2007 el Dr. Sastre-Garriga fue director médico de los centros de neurorehabilitación de la Fundación Esclerosis Múltiple (FEM). Desde el año 2007 trabaja como neurólogo clínico en el Servicio de Neurología/Neuroinmunología del Centro de Esclerosis Múltiple de Cataluña (Cemcat), Hospital Universitario Vall d’Hebron, Barcelona.


Proyectos / Línieas de investigación / Intereses

Sus intereses prinicipales son las técnicas de imagen por resonancia magnética (ressonancia magnética funcional y volumetría) y la neurorehabilitación especialmente en esclerosis múltiple primaria progresiva, una forma de la enfermedad a la que dedicó su investigación de doctorado.


Publicaciones

Las últimas 100 publicaciones

  1. Feys P, Sastre-Garriga J. Editorial. Mult Scler. 2019 Sep. PMID: 31469353

  2. Pareto D, Sastre-Garriga J, Alberich M, Auger C, Tintoré M, Montalban X, Rovira À. Brain regional volume estimations with NeuroQuant and FIRST: a study in patients with a clinically isolated syndrome. Neuroradiology. 2019 Jun. PMID: 30834955

  3. Zuluaga MI, Otero-Romero S, Rovira A, Perez-Hoyos S, Arrambide G, Negrotto L, Galán I, Río J, Comabella M, Nos C, Arévalo MJ, Vidal-Jordana A, Castilló J, Rodríguez B, Midaglia L, Mulero P, Mitjana R, Auger C, Sastre-Garriga J, Montalban X, Tintoré M. Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis. Neurology. 2019 Mar 26. PMID: 30824557

  4. Pappolla A, Midaglia L, Boix Rodríguez CP, Puig AA, Lung M, Camps IR, Castilló J, Mulero P, Vidal-Jordana A, Arrambide G, Rodriguez-Acevedo B, Sastre-Garriga J, Río J, Comabella M, Galán I, Tintoré M, Montalbán X. Simultaneous CMV and <i>Listeria</i> infection following alemtuzumab treatment for multiple sclerosis. Neurology. 2019 Feb 5. PMID: 30587519

  5. Gasperini C, Prosperini L, Tintoré M, Sormani MP, Filippi M, Rio J, Palace J, Rocca MA, Ciccarelli O, Barkhof F, Sastre-Garriga J, Vrenken H, Frederiksen JL, Yousry TA, Enzinger C, Rovira A, Kappos L, Pozzilli C, Montalban X, De Stefano N, and the MAGNIMS Study Group.. Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge. Neurology. 2019 Jan 22. PMID: 30587516

  6. Giordano A, Liethmann K, Köpke S, Poettgen J, Rahn AC, Drulovic J, Beckmann Y, Sastre-Garriga J, Galea I, Heerings M, Jongen PJ, Vettorazzi E, Solari A, Heesen C, AutoMS group.. Risk knowledge of people with relapsing-remitting multiple sclerosis - Results of an international survey. PLoS One. 2018. PMID: 30496233

  7. Glaser A, Stahmann A, Meissner T, Flachenecker P, Horáková D, Zaratin P, Brichetto G, Pugliatti M, Rienhoff O, Vukusic S, de Giacomoni AC, Battaglia MA, Brola W, Butzkueven H, Casey R, Drulovic J, Eichstädt K, Hellwig K, Iaffaldano P, Ioannidou E, Kuhle J, Lycke K, Magyari M, Malbaša T, Middleton R, Myhr KM, Notas K, Orologas A, Otero-Romero S, Pekmezovic T, Sastre-Garriga J, Seeldrayers P, Soilu-Hänninen M, Stawiarz L, Trojano M, Ziemssen T, Hillert J, Thalheim C. Multiple sclerosis registries in Europe - An updated mapping survey. Mult Scler Relat Disord. 2019 Jan. PMID: 30384204

  8. Tintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis - success from bench to bedside. Nat Rev Neurol. 2019 Jan. PMID: 30315270

  9. Rocca MA, Barkhof F, De Luca J, Frisén J, Geurts JJG, Hulst HE, Sastre-Garriga J, Filippi M, MAGNIMS Study Group.. The hippocampus in multiple sclerosis. Lancet Neurol. 2018 Oct. PMID: 30264730

  10. Midaglia L, Gratacòs M, Caronna E, Raguer N, Sastre-Garriga J, Montalban X, Tintoré M. Myasthenia gravis following alemtuzumab therapy for multiple sclerosis. Neurology. 2018 Sep 25. PMID: 30143565

  11. Köpke S, Giordano A, Veronese S, Christin Rahn A, Kleiter I, Basedow-Rajwich B, Fornari A, Battaglia MA, Drulovic J, Kooij L, Koops J, Mens J, Meza Murillo ER, Milanov I, Milo R, Patti F, Pekmezovic T, Sastre-Garriga J, Vosburgh J, Voltz R, Bay J, Oliver DJ, Solari A. Patient and caregiver involvement in the formulation of guideline questions: findings from the European Academy of Neurology guideline on palliative care of people with severe multiple sclerosis. Eur J Neurol. 2019 Jan. PMID: 30035845

  12. . Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - Commentary. Mult Scler. 2018 Oct. PMID: 30033805

  13. Amiri H, de Sitter A, Bendfeldt K, Battaglini M, Gandini Wheeler-Kingshott CAM, Calabrese M, Geurts JJG, Rocca MA, Sastre-Garriga J, Enzinger C, de Stefano N, Filippi M, Rovira Á, Barkhof F, Vrenken H, MAGNIMS Study Group.. Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI. Neuroimage Clin. 2018. PMID: 29984155

  14. Eshaghi A, Marinescu RV, Young AL, Firth NC, Prados F, Jorge Cardoso M, Tur C, De Angelis F, Cawley N, Brownlee WJ, De Stefano N, Laura Stromillo M, Battaglini M, Ruggieri S, Gasperini C, Filippi M, Rocca MA, Rovira A, Sastre-Garriga J, Geurts JJG, Vrenken H, Wottschel V, Leurs CE, Uitdehaag B, Pirpamer L, Enzinger C, Ourselin S, Gandini Wheeler-Kingshott CA, Chard D, Thompson AJ, Barkhof F, Alexander DC, Ciccarelli O. Progression of regional grey matter atrophy in multiple sclerosis. Brain. 2018 Jun 1. PMID: 29741648

  15. Storelli L, Rocca MA, Pagani E, Van Hecke W, Horsfield MA, De Stefano N, Rovira A, Sastre-Garriga J, Palace J, Sima D, Smeets D, Filippi M, MAGNIMS Study Group.. Measurement of Whole-Brain and Gray Matter Atrophy in Multiple Sclerosis: Assessment with MR Imaging. Radiology. 2018 Aug. PMID: 29714673

  16. Geraldes R, Ciccarelli O, Barkhof F, De Stefano N, Enzinger C, Filippi M, Hofer M, Paul F, Preziosa P, Rovira A, DeLuca GC, Kappos L, Yousry T, Fazekas F, Frederiksen J, Gasperini C, Sastre-Garriga J, Evangelou N, Jacqueline Palace on behalf of the MAGNIMS study group.. The current role of MRI in differentiating multiple sclerosis from its imaging mimics. Nat Rev Neurol. 2018 Mar 20. PMID: 29582852

  17. Geraldes R, Ciccarelli O, Barkhof F, De Stefano N, Enzinger C, Filippi M, Hofer M, Paul F, Preziosa P, Rovira A, DeLuca GC, Kappos L, Yousry T, Fazekas F, Frederiksen J, Gasperini C, Sastre-Garriga J, Evangelou N, Palace J, MAGNIMS study group.. The current role of MRI in differentiating multiple sclerosis from its imaging mimics. Nat Rev Neurol. 2018 Apr. PMID: 29521337

  18. Parmar K, Stadelmann C, Rocca MA, Langdon D, D'Angelo E, D'Souza M, Burggraaff J, Wegner C, Sastre-Garriga J, Barrantes-Freer A, Dorn J, Uitdehaag BMJ, Montalban X, Wuerfel J, Enzinger C, Rovira A, Tintore M, Filippi M, Kappos L, Sprenger T, MAGNIMS study group.. The role of the cerebellum in multiple sclerosis-150 years after Charcot. Neurosci Biobehav Rev. 2018 Jun. PMID: 29477616

  19. Camara-Lemarroy CR, Castilló J, Sastre-Garriga J, Tintore M, Montalban X. Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report. Mult Scler. 2018 Sep. PMID: 29473796

  20. Arrambide G, Tintore M, Espejo C, Auger C, Castillo M, Río J, Castilló J, Vidal-Jordana A, Galán I, Nos C, Mitjana R, Mulero P, de Barros A, Rodríguez-Acevedo B, Midaglia L, Sastre-Garriga J, Rovira A, Comabella M, Montalban X. The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. Brain. 2018 Apr 1. PMID: 29462277

  21. Sastre-Garriga J, Otero-Romero S. [Remodelling of the Scientific Committee and a new series of neuroepidemiology reviews]. Rev Neurol. 2018 Feb 16. PMID: 29435965

  22. Pareto D, Sastre-Garriga J, Alonso J, Galán I, Arévalo MJ, Renom M, Montalban X, Rovira À. Classic Block Design "Pseudo"-Resting-State fMRI Changes After a Neurorehabilitation Program in Patients with Multiple Sclerosis. J Neuroimaging. 2018 May. PMID: 29400912

  23. Eshaghi A, Prados F, Brownlee WJ, Altmann DR, Tur C, Cardoso MJ, De Angelis F, van de Pavert SH, Cawley N, De Stefano N, Stromillo ML, Battaglini M, Ruggieri S, Gasperini C, Filippi M, Rocca MA, Rovira A, Sastre-Garriga J, Vrenken H, Leurs CE, Killestein J, Pirpamer L, Enzinger C, Ourselin S, Wheeler-Kingshott CAMG, Chard D, Thompson AJ, Alexander DC, Barkhof F, Ciccarelli O, MAGNIMS study group.. Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann Neurol. 2018 Feb. PMID: 29331092

  24. Tur C, Moccia M, Barkhof F, Chataway J, Sastre-Garriga J, Thompson AJ, Ciccarelli O. Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. Nat Rev Neurol. 2018 Feb. PMID: 29326424

  25. . "Brain reserve" and "cognitive reserve" should always be taken into account when studying neurodegeneration - NO. Mult Scler. 2018 Apr. PMID: 29318919

  26. Aymerich FX, Auger C, Alonso J, Alberich M, Sastre-Garriga J, Tintoré M, Montalban X, Rovira A. Cervical Cord Atrophy and Long-Term Disease Progression in Patients with Primary-Progressive Multiple Sclerosis. AJNR Am J Neuroradiol. 2018 Feb. PMID: 29284602

  27. Midaglia L, Mora L, Mulero P, Sastre-Garriga J, Montalban X. [Rituximab: its efficacy, effectiveness and safety in the treatment of multiple sclerosis]. Rev Neurol. 2018 Jan 1. PMID: 29251340

  28. Arrambide G, Tintore M, Auger C, Río J, Castilló J, Vidal-Jordana A, Galán I, Nos C, Comabella M, Mitjana R, Mulero P, de Barros A, Rodríguez-Acevedo B, Midaglia L, Sastre-Garriga J, Rovira A, Montalban X. Lesion topographies in multiple sclerosis diagnosis: A reappraisal. Neurology. 2017 Dec 5. PMID: 29101276

  29. Sepúlveda M, Aldea M, Escudero D, Llufriu S, Arrambide G, Otero-Romero S, Sastre-Garriga J, Romero-Pinel L, Martínez-Yélamos S, Sola-Valls N, Armangué T, Sotoca J, Escartín A, Robles-Cedeño R, Ramió-Torrentà L, Presas-Rodríguez S, Ramo-Tello C, Munteis E, Pelayo R, Gubieras L, Brieva L, Ortiz N, Hervás M, Mañé-Martínez MA, Cano A, Vela E, Tintoré M, Blanco Y, Montalban X, Graus F, Saiz A. Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. Mult Scler. 2017 Oct 1. PMID: 28984163

  30. de Sitter A, Steenwijk MD, Ruet A, Versteeg A, Liu Y, van Schijndel RA, Pouwels PJW, Kilsdonk ID, Cover KS, van Dijk BW, Ropele S, Rocca MA, Yiannakas M, Wattjes MP, Damangir S, Frisoni GB, Sastre-Garriga J, Rovira A, Enzinger C, Filippi M, Frederiksen J, Ciccarelli O, Kappos L, Barkhof F, Vrenken H, MAGNIMS study group and for neuGRID.. Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study. Neuroimage. 2017 Dec. PMID: 28899746

  31. Preziosa P, Rocca MA, Mesaros S, Meani A, Montalban X, Drulovic J, Droby A, Zipp F, Calabrese M, Sastre-Garriga J, Dujmovic-Basuroski I, Rovira A, Filippi M. Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria. J Neurol Neurosurg Psychiatry. 2018 Mar. PMID: 28724720

  32. Rovira A, Auger C, Huerga E, Corral JF, Mitjana R, Sastre-Garriga J, Tintoré M, Montalban X. Cumulative Dose of Macrocyclic Gadolinium-Based Contrast Agent Improves Detection of Enhancing Lesions in Patients with Multiple Sclerosis. AJNR Am J Neuroradiol. 2017 Aug. PMID: 28619842

  33. Vidal-Jordana A, Sastre-Garriga J, Pareto D, Tur C, Arrambide G, Otero-Romero S, Huerga E, Mitjana R, Auger C, Tintoré M, Rovira A, Montalban X. Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations. Mult Scler. 2018 May. PMID: 28445084

  34. Sastre-Garriga J, Pareto D, Rovira À. Brain Atrophy in Multiple Sclerosis: Clinical Relevance and Technical Aspects. Neuroimaging Clin N Am. 2017 May. PMID: 28391787

  35. Arrambide G, Rovira A, Sastre-Garriga J, Tur C, Castilló J, Río J, Vidal-Jordana A, Galán I, Rodríguez-Acevedo B, Midaglia L, Nos C, Mulero P, Arévalo MJ, Comabella M, Huerga E, Auger C, Montalban X, Tintore M. Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. Mult Scler. 2018 Mar. PMID: 28301287

  36. Río J, Rovira À, Tintoré M, Otero-Romero S, Comabella M, Vidal-Jordana Á, Galán I, Castilló J, Arrambide G, Nos C, Tur C, Pujal B, Auger C, Sastre-Garriga J, Montalban X. Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients. Mult Scler. 2018 Mar. PMID: 28287331

  37. . [New areas, new challenges...] Rev Neurol. 2017 Mar 1. PMID: 28229438

  38. Vidal-Jordana A, Pareto D, Sastre-Garriga J, Auger C, Ciampi E, Montalban X, Rovira A. Measurement of Cortical Thickness and Volume of Subcortical Structures in Multiple Sclerosis: Agreement between 2D Spin-Echo and 3D MPRAGE T1-Weighted Images. AJNR Am J Neuroradiol. 2017 Feb. PMID: 27884876

  39. Tintore M, Otero-Romero S, Río J, Arrambide G, Pujal B, Tur C, Galán I, Comabella M, Nos C, Arévalo MJ, Vidal-Jordana A, Castilló J, Rodríguez-Acevedo B, Midaglia L, Mitjana R, Auger C, Sastre-Garriga J, Rovira À, Montalban X. Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis. Neurology. 2016 Sep 27. PMID: 27566747

  40. Arrambide G, Espejo C, Eixarch H, Villar LM, Alvarez-Cermeño JC, Picón C, Kuhle J, Disanto G, Kappos L, Sastre-Garriga J, Pareto D, Simon E, Comabella M, Río J, Nos C, Tur C, Castilló J, Vidal-Jordana A, Galán I, Arévalo MJ, Auger C, Rovira A, Montalban X, Tintore M. Neurofilament light chain level is a weak risk factor for the development of MS. Neurology. 2016 Sep 13. PMID: 27521440

  41. Aymerich FX, Auger C, Alcaide-Leon P, Pareto D, Huerga E, Corral JF, Mitjana R, Sastre-Garriga J, Montalban X, Rovira A. Comparison between gadolinium-enhanced 2D T1-weighted gradient-echo and spin-echo sequences in the detection of active multiple sclerosis lesions on 3.0T MRI. Eur Radiol. 2017 Apr. PMID: 27456965

  42. Tintoré M, Sastre-Garriga J. Multiple sclerosis: Dimethyl fumarate is coming of age. Nat Rev Neurol. 2016 Aug. PMID: 27448183

  43. Ciampi E, Pareto D, Sastre-Garriga J, Vidal-Jordana A, Tur C, Río J, Tintoré M, Auger C, Rovira A, Montalban X. Grey matter atrophy is associated with disability increase in natalizumab-treated patients. Mult Scler. 2017 Apr. PMID: 27354019

  44. . [A message from the new Editor of the Revista de Neurologia]. Rev Neurol. 2016 Jun 16. PMID: 27270673

  45. Otero-Romero S, Sastre-Garriga J, Comi G, Hartung HP, Soelberg Sørensen P, Thompson AJ, Vermersch P, Gold R, Montalban X. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. Mult Scler. 2016 Oct. PMID: 27207462

  46. . Leptomeningeal enhancement in Susac's syndrome and multiple sclerosis: Time to expect the unexpected? Mult Scler. 2016 Jun. PMID: 27207451

  47. Comabella M, Sastre-Garriga J, Montalban X. Precision medicine in multiple sclerosis: biomarkers for diagnosis, prognosis, and treatment response. Curr Opin Neurol. 2016 Jun. PMID: 27075495

  48. Midaglia L, Juega Mariño JM, Sastre-Garriga J, Rovira A, Vidal-Jordana A, López-Pérez MA, Marzo-Sola ME, Librada Escribano F, Montalban X. An uncommon first manifestation of multiple sclerosis: Tako-Tsubo cardiomyopathy. Mult Scler. 2016 May. PMID: 26993120

  49. Vidal-Jordana A, Sastre-Garriga J, Pérez-Miralles F, Pareto D, Rio J, Auger C, Tintoré M, Rovira A, Montalban X. Brain Volume Loss During the First Year of Interferon-Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics. J Neuroimaging. 2016 Sep. PMID: 26935253

  50. Pareto D, Sastre-Garriga J, Aymerich FX, Auger C, Tintoré M, Montalban X, Rovira A. Lesion filling effect in regional brain volume estimations: a study in multiple sclerosis patients with low lesion load. Neuroradiology. 2016 May. PMID: 26847633

  51. Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L, Rovira A, Sastre-Garriga J, Tintorè M, Frederiksen JL, Gasperini C, Palace J, Reich DS, Banwell B, Montalban X, Barkhof F, MAGNIMS Study Group.. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016 Mar. PMID: 26822746

  52. Valverde S, Oliver A, Roura E, Pareto D, Vilanova JC, Ramió-Torrentà L, Sastre-Garriga J, Montalban X, Rovira À, Lladó X. Quantifying brain tissue volume in multiple sclerosis with automated lesion segmentation and filling. Neuroimage Clin. 2015. PMID: 26740917

  53. Sastre-Garriga J, Wiendl H. Highlights from the 31st ECTRIMS congress - Barcelona 2015. Mult Scler. 2016 Jan. PMID: 26684283

  54. Enzinger C, Pinter D, Rocca MA, De Luca J, Sastre-Garriga J, Audoin B, Filippi M. Longitudinal fMRI studies: Exploring brain plasticity and repair in MS. Mult Scler. 2016 Mar. PMID: 26683590

  55. Otero-Romero S, Ramió-Torrentà L, Pericot I, Carmona O, Perkal H, Saiz A, Bufill E, Robles R, Simón E, Llufriu S, Vaqué-Rafart J, Sastre-Garriga J, Montalban X. Onset-adjusted incidence of multiple sclerosis in the Girona province (Spain): Evidence of increasing risk in the south of Europe. J Neurol Sci. 2015 Dec 15. PMID: 26671104

  56. Pareto D, Sastre-Garriga J, Auger C, Vives-Gilabert Y, Delgado J, Tintoré M, Montalban X, Rovira A. Juxtacortical Lesions and Cortical Thinning in Multiple Sclerosis. AJNR Am J Neuroradiol. 2015 Dec. PMID: 26450537

  57. Pérez-Miralles FC, Sastre-Garriga J, Vidal-Jordana A, Río J, Auger C, Pareto D, Tintoré M, Rovira A, Montalban X. Predictive value of early brain atrophy on response in patients treated with interferon β. Neurol Neuroimmunol Neuroinflamm. 2015 Aug. PMID: 26185778

  58. Vidal-Jordana A, Sastre-Garriga J, Rovira A, Montalban X. Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy. J Neurol. 2015 Dec. PMID: 26041617

  59. Tintore M, Rovira À, Río J, Otero-Romero S, Arrambide G, Tur C, Comabella M, Nos C, Arévalo MJ, Negrotto L, Galán I, Vidal-Jordana A, Castilló J, Palavra F, Simon E, Mitjana R, Auger C, Sastre-Garriga J, Montalban X. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain. 2015 Jul. PMID: 25902415

  60. Negrotto L, Tur C, Tintoré M, Arrambide G, Sastre-Garriga J, Río J, Comabella M, Nos C, Galán I, Vidal-Jordana A, Simon E, Castilló J, Palavra F, Mitjana R, Auger C, Rovira À, Montalban X. Should we systematically test patients with clinically isolated syndrome for auto-antibodies? Mult Scler. 2015 Dec. PMID: 25778697

  61. Martí G, Río J, Rovira À, Auger C, Tintoré M, Sastre-Garriga J, Vidal A, Castilló J, Montalban X. [Progressive multifocal leukoencephalopathy associated to natalizumab: the importance of magnetic resonance imaging in its early diagnosis]. Rev Neurol. 2015 Feb 16. PMID: 25670046

  62. Sastre-Garriga J, Tur C, Pareto D, Vidal-Jordana A, Auger C, Río J, Huerga E, Tintoré M, Rovira A, Montalban X. Brain atrophy in natalizumab-treated patients: A 3-year follow-up. Mult Scler. 2015 May. PMID: 25392330

  63. Vidal-Jordana A, Tintoré M, Tur C, Pérez-Miralles F, Auger C, Río J, Nos C, Arrambide G, Comabella M, Galán I, Castilló J, Sastre-Garriga J, Rovira A, Montalban X. Significant clinical worsening after natalizumab withdrawal: Predictive factors. Mult Scler. 2015 May. PMID: 25392320

  64. Montalban X, Sastre-Garriga J. Diagnosis and trials of clinically isolated syndrome. Lancet Neurol. 2014 Oct. PMID: 25192850

  65. Arrambide G, Sastre-Garriga J. Predictive markers of disease evolution after a CIS in everyday practice. J Neurol Sci. 2014 Aug 15. PMID: 24881867

  66. Flachenecker P, Buckow K, Pugliatti M, Kes VB, Battaglia MA, Boyko A, Confavreux C, Ellenberger D, Eskic D, Ford D, Friede T, Fuge J, Glaser A, Hillert J, Holloway E, Ioannidou E, Kappos L, Kasilingam E, Koch-Henriksen N, Kuhle J, Lepore V, Middleton R, Myhr KM, Orologas A, Otero S, Pitschnau-Michel D, Rienhoff O, Sastre-Garriga J, Schyns-Liharska T, Sutovic D, Thalheim C, Trojano M, Vlasov YV, Yaldizli O, EUReMS Consortium.. Multiple sclerosis registries in Europe - results of a systematic survey. Mult Scler. 2014 Oct. PMID: 24777278

  67. Heesen C, Bruce J, Feys P, Sastre-Garriga J, Solari A, Eliasson L, Matthews V, Hausmann B, Ross AP, Asano M, Imonen-Charalambous K, Köpke S, Clyne W, Bissell P. Adherence in multiple sclerosis (ADAMS): classification, relevance, and research needs. A meeting report. Mult Scler. 2014 Nov. PMID: 24756569

  68. Río J, Rovira A, Tintoré M, Sastre-Garriga J, Castilló J, Auger C, Nos C, Comabella M, Tur C, Vidal Á, Montalbán X. Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients. Mult Scler. 2014 Oct. PMID: 24622350

  69. Jarius S, Kleffner I, Dörr JM, Sastre-Garriga J, Illes Z, Eggenberger E, Chalk C, Ringelstein M, Aktas O, Montalban X, Fechner K, Stöcker W, Ringelstein EB, Paul F, Wildemann B. Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study. J Neuroinflammation. 2014 Mar 8. PMID: 24606999

  70. Penner IK, Sastre-Garriga J. One step forward in the quest for evidence of the efficacy of cognitive rehabilitation in multiple sclerosis. Mult Scler. 2014 Jan. PMID: 24347477

  71. Tur C, Tintoré M, Vidal-Jordana Á, Bichuetti D, Nieto González P, Arévalo MJ, Arrambide G, Anglada E, Galán I, Castilló J, Nos C, Río J, Martín MI, Comabella M, Sastre-Garriga J, Montalban X. Risk acceptance in multiple sclerosis patients on natalizumab treatment. PLoS One. 2013. PMID: 24340060

  72. Lucas-Carrasco R, Sastre-Garriga J, Galán I, Den Oudsten BL, Power MJ. Preliminary validation study of the Spanish version of the satisfaction with life scale in persons with multiple sclerosis. Disabil Rehabil. 2014. PMID: 23962197

  73. Kearney H, Rocca MA, Valsasina P, Balk L, Sastre-Garriga J, Reinhardt J, Ruggieri S, Rovira A, Stippich C, Kappos L, Sprenger T, Tortorella P, Rovaris M, Gasperini C, Montalban X, Geurts JJ, Polman CH, Barkhof F, Filippi M, Altmann DR, Ciccarelli O, Miller DH, Chard DT. Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. Mult Scler. 2014 Jan. PMID: 23812283

  74. Pérez-Miralles F, Sastre-Garriga J, Tintoré M, Arrambide G, Nos C, Perkal H, Río J, Edo MC, Horga A, Castilló J, Auger C, Huerga E, Rovira A, Montalban X. Clinical impact of early brain atrophy in clinically isolated syndromes. Mult Scler. 2013 Dec. PMID: 23652215

  75. Popescu V, Agosta F, Hulst HE, Sluimer IC, Knol DL, Sormani MP, Enzinger C, Ropele S, Alonso J, Sastre-Garriga J, Rovira A, Montalban X, Bodini B, Ciccarelli O, Khaleeli Z, Chard DT, Matthews L, Palace J, Giorgio A, De Stefano N, Eisele P, Gass A, Polman CH, Uitdehaag BM, Messina MJ, Comi G, Filippi M, Barkhof F, Vrenken H, MAGNIMS Study Group.. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013 Oct. PMID: 23524331

  76. Rovira À, Sastre-Garriga J, Auger C, Rovira A. Idiopathic inflammatory demyelinating diseases of the brainstem. Semin Ultrasound CT MR. 2013 Apr. PMID: 23522777

  77. Lansley J, Mataix-Cols D, Grau M, Radua J, Sastre-Garriga J. Localized grey matter atrophy in multiple sclerosis: a meta-analysis of voxel-based morphometry studies and associations with functional disability. Neurosci Biobehav Rev. 2013 Jun. PMID: 23518268

  78. Vidal-Jordana A, Sastre-Garriga J, Pérez-Miralles F, Tur C, Tintoré M, Horga A, Auger C, Río J, Nos C, Edo MC, Arévalo MJ, Castilló J, Rovira A, Montalban X. Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Mult Scler. 2013 Aug. PMID: 23319072

  79. Pugliatti M, Eskic D, Mikolcić T, Pitschnau-Michel D, Myhr KM, Sastre-Garriga J, Otero S, Wieczynska L, Torje C, Holloway E, Rienhoff O, Friede T, Buckow K, Ellenberger D, Hillert J, Glaser A, Flachenecker P, Fuge J, Schyns-Liharska T, Kasilingam E, Moretti A, Thalheim C, EUReMS Consortium.. Assess, compare and enhance the status of Persons with Multiple Sclerosis (MS) in Europe: a European Register for MS. Acta Neurol Scand Suppl. 2012. PMID: 23278653

  80. López-Méndez P, Río J, Pérez-Ricart A, Tintoré M, Sastre-Garriga J, Cardona-Pascual I, Gómez-Domingo MR, Montalban X. [Therapy adherence to immunomodulator treatment in patients with multiple sclerosis]. Rev Neurol. 2013 Jan 1. PMID: 23250676

  81. Costa C, Arrambide G, Tintore M, Castilló J, Sastre-Garriga J, Tur C, Río J, Saiz A, Vidal-Jordana A, Auger C, Nos C, Rovira A, Comabella M, Horga A, Montalban X. Value of NMO-IgG determination at the time of presentation as CIS. Neurology. 2012 May 15. PMID: 22551725

  82. Otero-Romero S, Roura P, Solà J, Altimiras J, Sastre-Garriga J, Nos C, Vaqué J, Montalban X, Bufill E. Increase in the prevalence of multiple sclerosis over a 17-year period in Osona, Catalonia, Spain. Mult Scler. 2013 Feb. PMID: 22546846

  83. Vidal-Jordana Á, Sastre-Garriga J, Montalban X. [Optical coherence tomography in multiple sclerosis]. Rev Neurol. 2012 May 1. PMID: 22532220

  84. Tur C, Tintoré M, Vidal-Jordana A, Castilló J, Galán I, Río J, Arrambide G, Comabella M, Arévalo MJ, Horno R, Vicente MJ, Caminero A, Nos C, Sastre-Garriga J, Montalban X. Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision. Mult Scler. 2012 Aug. PMID: 22383232

  85. Río J, Tintoré M, Sastre-Garriga J, Nos C, Castilló J, Tur C, Comabella M, Montalban X. Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. Eur J Neurol. 2012 Jun. PMID: 22289050

  86. Tur C, Montalban X, Tintoré M, Nos C, Río J, Aymerich FX, Brieva L, Téllez N, Perkal H, Comabella M, Galán I, Calle D, Sastre-Garriga J, Rovira A. Interferon β-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up. Arch Neurol. 2011 Nov. PMID: 22084124

  87. Sastre-Garriga J, Rovira A, Bonaventura I, Escudero-Torrella J, Marco-Igual M, Aymerich X, de Andres C, Lacruz F, Escartin A, Olascoaga J, Solar D, Farres J, Arroyo-Gonzalez R, Montalban X, En Nombre Del Grupo de Investigadores Del Estudio Prem.. [Spanish multi-centre observational study of the first attacks suggestive of multiple sclerosis: the PREM cohort]. Rev Neurol. 2011 Nov 16. PMID: 22052172

  88. Sastre-Garriga J, Montalban X. [Monoclonal antibodies in [corrected] development in [corrected] multiple sclerosis]. Neurologia. 2011 Nov. PMID: 21481981

  89. Sastre-Garriga J, Vila C, Clissold S, Montalban X. THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis. Expert Rev Neurother. 2011 May. PMID: 21456949

  90. Horga A, Castillo J, Rio J, Tintore M, Auger C, Sastre-Garriga J, Edo MC, Perez-Miralles F, Tur C, Nos C, Huerga E, Comabella M, Rovira A, Montalban X. An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis. Rev Neurol. 2011 Mar 16. PMID: 21387248

  91. Sastre-Garriga J, Alonso J, Renom M, Arévalo MJ, González I, Galán I, Montalban X, Rovira A. A functional magnetic resonance proof of concept pilot trial of cognitive rehabilitation in multiple sclerosis. Mult Scler. 2011 Apr. PMID: 21177323

  92. Lucas-Carrasco R, Pascual-Sedano B, Galán I, Kulisevsky J, Sastre-Garriga J, Gómez-Benito J. Using the WHOQOL-DIS to measure quality of life in persons with physical disabilities caused by neurodegenerative disorders. Neurodegener Dis. 2011. PMID: 21135535

  93. Sastre-Garriga J, Tintoré M. Multiple sclerosis: Lesion location may predict disability in multiple sclerosis. Nat Rev Neurol. 2010 Dec. PMID: 21131911

  94. Mendioroz M, Fernández-Cadenas I, Del Río-Espinola A, Rovira A, Solé E, Fernández-Figueras MT, García-Patos V, Sastre-Garriga J, Domingues-Montanari S, Alvarez-Sabín J, Montaner J. A missense HTRA1 mutation expands CARASIL syndrome to the Caucasian population. Neurology. 2010 Nov 30. PMID: 21115960

  95. Tintore M, Rovira A, Arrambide G, Mitjana R, Río J, Auger C, Nos C, Edo MC, Castilló J, Horga A, Perez-Miralles F, Huerga E, Comabella M, Sastre-Garriga J, Montalban X. Brainstem lesions in clinically isolated syndromes. Neurology. 2010 Nov 23. PMID: 21098409

  96. Otero S, Batlle J, Bonaventura I, Brieva L, Bufill E, Cano A, Carmona O, Escartín A, Marco M, Moral E, Munteis E, Nos C, Pericot I, Perkal H, Ramió-Torrentà L, Ramo-Tello C, Saiz A, Sastre-Garriga J, Tintoré M, Vaqué J, Montalban X, Grupo de Trabajo del Registro de Esclerosis Múltiple de Cataluña.. [Multiple sclerosis epidemiological situation update: pertinence and set-up of a population based registry of new cases in Catalonia]. Rev Neurol. 2010 May 16. PMID: 20473839

  97. Flachenecker P, Khil L, Bergmann S, Kowalewski M, Pascu I, Pérez-Miralles F, Sastre-Garriga J, Zwingers T. Development and pilot phase of a European MS register. J Neurol. 2010 Oct. PMID: 20443020

  98. Montalban X, Sastre-Garriga J, Filippi M, Khaleeli Z, Téllez N, Vellinga MM, Tur C, Brochet B, Barkhof F, Rovaris M, Miller DH, Polman CH, Rovira A, Thompson AJ. Primary progressive multiple sclerosis diagnostic criteria: a reappraisal. Mult Scler. 2009 Dec. PMID: 19995843

  99. Sastre-Garriga J, Tintoré M, Nos C, Tur C, Río J, Téllez N, Castilló J, Horga A, Perkal H, Comabella M, Rovira A, Montalban X. Clinical features of CIS of the brainstem/cerebellum of the kind seen in MS. J Neurol. 2010 May. PMID: 19946780

  100. Montalban X, Sastre-Garriga J, Tintoré M, Brieva L, Aymerich FX, Río J, Porcel J, Borràs C, Nos C, Rovira A. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler. 2009 Oct. PMID: 19797261

Las publicaciones que se indican derivan automáticamente de PubMed. Esto puede hacer que se muestren publicaciones incorrectas o que falte alguna de ellas.


View more...